). Goldman Sachs US Lead Biotechnology Analyst Salveen Richter joins Catalysts to discuss the state of the weight-loss market and the potential headwinds for these pharmaceutical companies.She notes that Eli Lilly and Novo Nordisk are facing limited supply as demand skyrockets.
And then we're watching Regeneron as a player going after the quality or body proportionality of weight loss.So they're trying to address that side of the story. Um So I think when we start to see them expand on manufacturing, but also these new entrants coming in who have manufacturing capa capacity like Amgen talked about at length about their ability to manufacture here that should kind of aid and also you'll have a differentiated approach, right?So I mean, when it comes to the ability to meet that demand, right?What every what so many of these bigger players are doing, trying to address that.
And so I think there's going to be significant investment, maybe there's a way to use contract manufacturing organizations and bring them into the process here.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
La source: YahooFinanceCA - 🏆 47. / 63 Lire la suite »